Amneal Pharmaceuticals, Inc. (AMRX)
| Market Cap | 730.76M |
| Revenue (ttm) | 1.88B |
| Net Income (ttm) | 61.97M |
| Shares Out | 147.56M |
| EPS (ttm) | 0.42 |
| PE Ratio | 11.84 |
| Forward PE | 7.37 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $4.95 |
| Previous Close | $4.85 |
| Change ($) | 0.10 |
| Change (%) | 2.06% |
| Day's Open | 4.80 |
| Day's Range | 4.80 - 5.00 |
| Day's Volume | 1,239,960 |
| 52-Week Range | 2.46 - 5.46 |
BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and commercialize Anti-PD-1 antibody Tisleliz...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE:AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced they have entered into a definitive agreement...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that it has received approval of an additional strength of 500 mg to its Abb...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal's Co-Chief Executive Officer and President, will present...
As part of its outlook for biopharma companies in 2021, Guggenheim Securities turned bullish on Amneal Pharmaceuticals Inc (NYSE: AMRX). The Amneal Analyst: Dana Flanders upgraded Amneal from ...
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.
Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the ...
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2020 Results - Earnings Call Transcript
Shares of Amneal Pharmaceuticals (NYSE:AMRX) rose 1.0% in pre-market trading after the company reported Q3 results.
Amneal (AMRX) delivered earnings and revenue surprises of 23.08% and 8.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the third quarter ended September 30, 2020. “Amneal delivered anot...
Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) closed at $4.36 in the latest trading session, marking a -1.13% move from the prior day.
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is (AMRX) Outperforming Other Medical Stocks This Year?
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2020 financial results on Friday, November 6, 2020...
--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE:AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distri...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal’ or the “Company”) and PL Developments (PLD) today announced that they have commenced shipments of store ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q2 2020 Results - Earnings Call Transcript
Amneal (AMRX) delivered earnings and revenue surprises of 30.00% and 3.73%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc.
Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Amneal Pharmaceuticals (AMRX) closed at $4.46, marking a +0.45% move from the previous day.
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.86, moving +0.21% from the previous trading session.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval ...
Amneal Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Amneal Pharmaceuticals, Inc. (AMRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
As of late, it has definitely been a great time to be an investor in Amneal Pharmaceuticals.
Amneal (AMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amneal Pharmaceuticals Inc. (AMRX) CEO Chirag Patel on Q1 2020 Results - Earnings Call Transcript
Amneal (AMRX) delivered earnings and revenue surprises of 150.00% and 12.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Amneal Pharmaceuticals (NYSE:AMRX) moved higher by 13% in pre-market trading after the company reported Q1 results.
Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Healthcare bargain hunters can find good values in quality low-priced stocks.
Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.
Amneal (AMRX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
The company expects to produce around 20 million tablets within a month.
No, but doctors can still use the drugs despite limited evidence of their effectiveness.
The online pharmacy conducted its own tests of the type-2 diabetes drug and found excessive levels of a carcinogenic compound in 42% of the batches it tested.
Amneal Pharmaceuticals Inc. (AMRX) CEO Chirag Patel on Q4 2019 Results - Earnings Call Transcript
Amneal (AMRX) delivered earnings and revenue surprises of 60.00% and 3.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
About AMRX
Amneal Pharmaceuticals, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manuf... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 2002 |
| CEO Chirag K. Patel | Employees 5,500 |
| Stock Exchange NYSE | Ticker Symbol AMRX |
Financial Performance
In 2019, AMRX's revenue was $1.63 billion, a decrease of -2.20% compared to the previous year's $1.66 billion. Losses were -$361.92 million, 1,630.0% more than in 2018.
Analyst Forecasts
According to 12 analysts, the average rating for AMRX stock is "Hold." The 12-month stock price forecast is 4.83, which is a decrease of -2.42% from the latest price.